N. Nicholson

发表

Assessment of Bleeding Propensity in Non-Human Primates by Combination of Selective Tissue Factor/VIIa Inhibition and Aspirin Compared to Warfarin and Aspirin Treatment

M. S. South, J. J. Parlow, A. Salyers, 2004, Pharmacology.

Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist

R. Anders, A. Salyers, J. A. Szalony, 2001, Medicinal research reviews.

A New Model of Dual Interacting Ligand Binding Sites on Integrin αIIbβ3 *

Jeffrey W. Smith, N. Nicholson, D. Hu, 1999, The Journal of Biological Chemistry.

Characterization of Binding of an RGD Mimetic, [(3)H]-SC-52012, to Platelet GPIIb/IIIa.

P. Jacqmin, J. Zablocki, L. Feigen, 1995, Platelets.

SC-49992--a potent and specific inhibitor of platelet aggregation.

T. Giorgio, L. Feigen, V. Engleman, 1994, Thrombosis research.

In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent.

R. Gorczynski, M. E. Zupec, A. Salyers, 1991, Thrombosis research.

Pharmacological Intervention at Disparate Sites in the Coagulation Cascade: Comparison of Anti-thrombotic Efficacy vs. Bleeding Propensity in a Rat Model of Acute Arterial Thrombosis

T. Girard, J. A. Szalony, N. Nicholson, 2002, Journal of Thrombosis and Thrombolysis.

Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time.

M. S. South, J. J. Parlow, A. Salyers, 2003, Thrombosis research.

Pharmacological Interruption of Acute Thrombus Formation with Minimal Hemorrhagic Complications by a Small Molecule Tissue Factor/Factor VIIa Inhibitor: Comparison to Factor Xa and Thrombin Inhibition in a Nonhuman Primate Thrombosis Model

M. S. South, J. J. Parlow, A. Salyers, 2003, Journal of Pharmacology and Experimental Therapeutics.

Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist

R. Anders, A. Salyers, J. A. Szalony, 2001, Medicinal research reviews.

Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin.

L. Feigen, A. Salyers, J. A. Szalony, 1998, Circulation.

The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation.

T. Girard, N. Nicholson, 2001, Current opinion in pharmacology.

Aminopeptidase resistant Arg-Gly-Asp analogs are stable in plasma and inhibit platelet aggregation.

L. Feigen, S. Adams, K. Fok, 2009, International journal of peptide and protein research.

Effect of 23-methyl-21-norcholest-5-ene-3β,23,25-triol on hepatic cholesterol 7α-hydroxylase activity in the rat

N. Nicholson, B. N. Desai, L. Flanders, 1979 .

A radioreceptor binding assay for measurement of platelet-activating factor synthesis by human neutrophils.

S. Paulson, N. Nicholson, 1988, Journal of immunological methods.

Effect of the stable endoperoxide analog U-46619 on prostacyclin production and cyclic AMP levels in bovine endothelial cells.

N. Nicholson, G. Fuller, S. Smith, 1984, Thrombosis research.

The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis.

L. Feigen, A. Salyers, O. D. Suleymanov, 1996, Circulation.

Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A.

D. Mehrotra, L. Feigen, A. Salyers, 1995, Circulation.

Fibrinogen receptor antagonists

J. Zablocki, L. Feigen, N. Nicholson, 1994 .

Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.

R. Kurumbail, W. Stallings, A. Stevens, 2003, Journal of medicinal chemistry.

Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.

R. Kurumbail, W. Stallings, A. Stevens, 2003, Bioorganic & medicinal chemistry letters.

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor.

J. Zablocki, M. Miyano, N. Nicholson, 1993, Journal of medicinal chemistry.

Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor.

J. Zablocki, L. Feigen, M. Miyano, 1992, Journal of medicinal chemistry.

Assessment of platelet function assays.

L. Feigen, L P Feigen, D M Lansky, 1998, American heart journal.

SC-54684A: an orally active inhibitor of platelet aggregation.

J. Zablocki, B. Keller, A. Salyers, 1995, Circulation.

Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation.

D. Mehrotra, L. Feigen, N. Nicholson, 1993, Journal of pharmacological and toxicological methods.

Evaluation of a stable 5-F prostacyclin analogue as an antithrombotic agent in haemodialysis.

N. Nicholson, G. Fuller, B. Taite, 1986, Drugs under experimental and clinical research.

The structure of ribonuclease P protein from Staphylococcus aureus reveals a unique binding site for single-stranded RNA.

C. Prescott, R. Lehr, C. Spitzfaden, 2000, Journal of molecular biology.

A new model of dual interacting ligand binding sites on integrin alphaIIbbeta3.

J. Smith, N. Nicholson, D. Hu, 1999, The Journal of biological chemistry.

Studies on semen from rabbits injected with H 3 -thymidine and treated with prostaglandins E 2 and F 2 .

N. Nicholson, W. L. Hunt, 1972, Fertility and sterility.

Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749).

R. Gorczynski, M. E. Zupec, A. Salyers, 1991, Journal of Pharmacology and Experimental Therapeutics.

A method for determining whether hypotension caused by novel compounds in preclinical development results from histamine release.

C. Wegner, M. S. South, J. J. Parlow, 2004, Journal of pharmacological and toxicological methods.